During the past decade, CH Albi conducted 6 clinical trials. In the 10-year time frame, 6 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CH Albi" #1 sponsor was "LivaNova" with 4 trials, followed by "University Hospital, Toulouse" with 4 trials sponsored, "Federation Francophone de Cancerologie Digestive" with 2 trials sponsored, "Boston Scientific Corporation" with 1 trials sponsored and "Centre Hospitalier Universitaire de Nīmes" with 1 trials sponsored. Other sponsors include 3 different institutions and companies that sponsored additional 13 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CH Albi" #1 collaborator was "Agence Régionale de la Santé - Midi Pyrénées" with 1 trials as a collaborator, "CENTRE HOSPITALIER COMMINGES PYRENEES" with 1 trials as a collaborator, "Centre Hospitalier Ales" with 1 trials as a collaborator, "Centre Hospitalier Intercommunal de Castres" with 1 trials as a collaborator and "Centre Hospitalier d'Albi" with 1 trials as a collaborator. Other collaborators include 8 different institutions and companies that were collaborators in the rest 18 trials.

According to Clinical.Site data, the most researched conditions in "CH Albi" are "Alzheimer's Disease" (2 trials), "Acute Coronary Syndrome" (1 trials), "Atrial Arrhythmia" (1 trials), "Biventricular Tachycardias" (1 trials) and "Bradycardia-Tachycardia Syndrome" (1 trials). Many other conditions were trialed in "CH Albi" in a lesser frequency.

Most popular intervention types in "CH Albi" are "Device" (5 trials), "Drug" (5 trials), "Other" (4 trials), "Behavioral" (1 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Appropriateness of NH resident's transfer to ED" (1 trials), "Botulinum toxin type A" (1 trials), "CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin" (1 trials), "FOLFOX4 or XELOX" (1 trials) and "Global care and support program" (1 trials). Other intervention names were less common.

The vast majority of trials in "CH Albi" are 20 trials for "All" genders.

Currently, there are NaN active trials in "CH Albi". undefined are not yet recruiting, 4 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 15 completed trials in CH Albi, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in CH Albi, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 4 trials that are defined as “Not Applicable".